ReviewHypertension research : official journal of the Japanese Society of Hypertension2025
Renin-angiotensin-aldosterone system and its relation to hypertension.
Review in Hypertension research : official journal of the Japanese Society of Hypertension, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of aldosterone synthase inhibitors for uncontrolled hypertension: a meta-analysis of randomized controlled trials and systematic review.Frontiers in pharmacology · 2025Pooled it
- Protective Arm of Renin-Angiotensin System: Evidence of Nephroprotective Effects Against Acute Kidney Injury.Acta physiologica (Oxford, England) · 2026Review
- Article
- The Role of the Renin-Angiotensin-Aldosterone System in Hypertensive Emergencies.Biomedicines · 2026Review
- Aldosterone Synthase Inhibition in Diabetes and Cardiorenal Metabolic Disease.Journal of diabetes · 2026Article
- Causal effects among hypertension, osteoporosis, and metabolites: A Mendelian randomization study.Journal of the Chinese Medical Association : JCMA · 2026Article
- Article
- Present and Future Options for Pharmacotherapy in Cardiovascular Disease: Hemodynamic and Mechanistic Therapeutic Targets.Medical sciences (Basel, Switzerland) · 2026Review
- COVID-19 and cardiovascular outcomes in patients with pre-existing hypertension.Journal of human hypertension · 2026Review
- Myeloid transglutaminase 2 regulates Treg-Th17 balance in a female model of angiotensin II-induced hypertension and vascular stiffening.American journal of physiology. Heart and circulatory physiology · 2026Article
- Psychological Scars and Physical Consequences: Linking PTSD to Cardiovascular Health.Journal of cardiovascular translational research · 2026Review
- Sepsis in multimorbidity: a domain-based framework for systemic vulnerability and precision care.Frontiers in medicine · 2026Review
- Association analysis of obesity and hypertension and research on ethnic heterogeneity: a cross-sectional study based on different populations in Northwest China.BMC public health · 2025Article
- Hyperuricemia-induced kidney injury: a narrative review of mechanisms and therapeutic advances.BMC nephrology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regulation of the renin-angiotensin-aldosterone system plays an important role in the onset and progression of hypertension. In this system, there are two types of angiotensin II (Ang II) receptors: type 1 (AT
Indexed as
Identifiers
40437114What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.